Cover Image

Impact of Growth Conditions on High-Throughput Identification of Repurposing Drugs for <i>Pseudomonas aeruginosa</i> Cystic Fibrosis Lung Infections

<i>Pseudomonas aeruginosa</i> lung infections in cystic fibrosis (CF) patients represent a therapeutic challenge due to antibiotic resistance. Repurposing existing drugs is a promising approach for identifying new antimicrobials. A crucial factor in successful drug repurposing is using a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Giovanni Di Bonaventura (Author), Veronica Lupetti (Author), Arianna Pompilio (Author)
Format:	Book
Published:	MDPI AG, 2024-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Antibacterial and Antibiofilm Effects of Lactobacilli Strains against Clinical Isolates of <i>Pseudomonas aeruginosa</i> under Conditions Relevant to Cystic Fibrosis
by: Giovanna Batoni, et al.
Published: (2023)

Clonal Diversity, Biofilm Formation, and Antimicrobial Resistance among <i>Stenotrophomonas maltophilia</i> Strains from Cystic Fibrosis and Non-Cystic Fibrosis Patients
by: Arianna Pompilio, et al.
Published: (2020)

Inflammatory Markers in Cystic Fibrosis Patients with Lung Pseudomonas Aeruginosa Infection
by: A. L. Pukhalsky, et al.
Published: (1999)

Virulence of <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis: Relationships between Normoxia and Anoxia Lifestyle
by: Rosanna Papa, et al.
Published: (2023)

Ticarcillin Hypersusceptibility in Pseudomonas Aeruginosa in Cystic Fibrosis
by: IT Hettiarachchi, et al.
Published: (2017)

Polymicrobial Interactions in the Cystic Fibrosis Airway Microbiome Impact the Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i>
by: Emma Reece, et al.
Published: (2021)

Current and Emerging Inhaled Antibiotics for Chronic Pulmonary <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> Infections in Cystic Fibrosis
by: Danni Li, et al.
Published: (2023)

The Anti-Microbial Peptide (Lin-SB056-1)<sub>2</sub>-K Reduces Pro-Inflammatory Cytokine Release through Interaction with <i>Pseudomonas aeruginosa</i> Lipopolysaccharide
by: Lucia Grassi, et al.
Published: (2020)

Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in an In Vitro Cystic Fibrosis Sputum Model
by: Vaughn D. Craddock, et al.
Published: (2023)

High-Throughput Transcriptomic Profiling Reveals the Inhibitory Effect of Hydroquinine on Virulence Factors in <i>Pseudomonas aeruginosa</i>
by: Nontaporn Rattanachak, et al.
Published: (2022)

New Sequence Type ST3449 in Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Isolates from a Cystic Fibrosis Patient
by: Catalina Díaz-Ríos, et al.
Published: (2021)

<i>Pseudomonas aeruginosa</i> Biofilm Formation, Infections and Treatments
Published: (2021)

Identification of Efflux Pump Mutations in <i>Pseudomonas aeruginosa</i> from Clinical Samples
by: Sonia Quddus, et al.
Published: (2023)

Lytic Bacteriophage Is a Promising Adjunct to Common Antibiotics across Cystic Fibrosis Clinical Strains and Culture Models of <i>Pseudomonas aeruginosa</i> Infection
by: Isaac Martin, et al.
Published: (2023)

Effects of Levofloxacin, Aztreonam, and Colistin on Enzyme Synthesis by <i>P. aeruginosa</i> Isolated from Cystic Fibrosis Patients
by: Arianna Pani, et al.
Published: (2022)

Repurposing Mitomycin C in Combination with Pentamidine or Gentamicin to Treat Infections with Multi-Drug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>
by: Elin Svedholm, et al.
Published: (2024)

Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status
by: Hraiech S, et al.
Published: (2015)

Antimicrobial Synergy Testing: Comparing the Tobramycin and Ceftazidime Gradient Diffusion Methodology Used in Assessing Synergy in Cystic Fibrosis-Derived Multidrug-Resistant <i>Pseudomonas aeruginosa</i>
by: Ijeoma N. Okoliegbe, et al.
Published: (2021)

Treatment Heterogeneity in <i>Pseudomonas aeruginosa</i> Pneumonia
by: Aisling R. Caffrey, et al.
Published: (2022)

Drug Repurposing Targeting <i>Pseudomonas aeruginosa</i> MvfR Using Docking, Virtual Screening, Molecular Dynamics, and Free-Energy Calculations
by: Tatiana F. Vieira, et al.
Published: (2022)

Anti-Virulence Activity of the Cell-Free Supernatant of the Antarctic Bacterium <i>Psychrobacter</i> sp. TAE2020 against <i>Pseudomonas aeruginosa</i> Clinical Isolates from Cystic Fibrosis Patients
by: Rosanna Papa, et al.
Published: (2021)

Novel understandings of host cell mechanisms involved in chronic lung infection: Pseudomonas aeruginosa in the cystic fibrotic lung
by: Peter Anto Johnson
Published: (2019)

Clinical Course of Children with Chronic Suppurative Lung Disease or Bronchiectasis Infected with <i>Pseudomonas aeruginosa</i>
by: Elpiniki Kartsiouni, et al.
Published: (2022)

Non-Linear Pharmacokinetics of Oral Roscovitine (Seliciclib) in Cystic Fibrosis Patients Chronically Infected with <i>Pseudomonas aeruginosa</i>: A Study on Population Pharmacokinetics with Monte Carlo Simulations
by: Cyril Leven, et al.
Published: (2020)

Caracterización, por RAPD-PCR, de aislados de Pseudomonas aeruginosa obtenidos de pacientes con fibrosis quística RAPD-PCR characterization of Pseudomonas aeruginosa strains obtained from cystic fibrosis patients
by: Maribel Ortiz-Herrera, et al.
Published: (2004)

Therapeutic Approach of Chronic <i>Pseudomonas</i> Infection in Cystic Fibrosis-A Network Meta-Analysis
by: Orsolya Varannai, et al.
Published: (2021)

Antimicrobial Treatment of <i>Pseudomonas aeruginosa</i> Severe Sepsis
by: Johnny Zakhour, et al.
Published: (2022)

The Basis for Natural Multiresistance to Phage in <i>Pseudomonas aeruginosa</i>
by: Christine Pourcel, et al.
Published: (2020)

THE PERFORMANCE OF A LONG-TERM ANTIBACTERIAL THERAPY IN CHILDREN WITH CYSTIC FIBROSIS DURING PRIMARY PLATING OF PSEUDOMONAS AERUGINOSA
by: О. I. Simonova, et al.
Published: (2014)

Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data
by: Silvia Garazzino, et al.
Published: (2020)

Intravenous Fosfomycin for Systemic Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections
by: Giuseppe Pipitone, et al.
Published: (2023)

Spiramycin Disarms <i>Pseudomonas aeruginosa</i> without Inhibiting Growth
by: Matteo Calcagnile, et al.
Published: (2023)

Bacteriophage-Antibiotic Combination Therapy against <i>Pseudomonas aeruginosa</i>
by: Guillermo Santamaría-Corral, et al.
Published: (2023)

Sub-Inhibitory Antibiotic Exposure and Virulence in <i>Pseudomonas aeruginosa</i>
by: Charlotte Nolan, et al.
Published: (2021)

Detection of extended-spectrum β-lactamase in <i>Pseudomonas aeruginosa</i>
by: Aggarwal Ritu, et al.
Published: (2008)

Vitamin D inhibits pro-inflammatory cytokines in the airways of cystic fibrosis patients infected by Pseudomonas aeruginosa- pilot study
by: M. Olszowiec-Chlebna, et al.
Published: (2019)

Myeloperoxidase and eosinophil cationic protein in serum and sputum during antibiotic treatment in cystic fibrosis patients with Pseudomonas aeruginosa infection
by: B. Niggemann, et al.
Published: (1995)

Repurposing existing drugs: identification of irreversible IMPDH inhibitors by high-throughput screening
by: Albertus Eka Yudistira Sarwono, et al.
Published: (2019)

Trends in <i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa</i>) Bacteremia during the COVID-19 Pandemic: A Systematic Review
by: Qin Xiang Ng, et al.
Published: (2023)

Identification of the PA1113 Gene Product as an ABC Transporter Involved in the Uptake of Carbenicillin in <i>Pseudomonas aeruginosa</i> PAO1
by: Christian Hulen, et al.
Published: (2020)